StockWatch: Pfizer Vaccine to Boost Revenues for Years
Demand for Pfizer’s Covid-19 vaccine could boost its revenues for years.
Pfizer said it expected to sign more deals this year with several countries for 2022 and beyond.
Denmark became the first country to exclude Johnson & Johnson’s Covid-19 jabs from its vaccination program, over a potential link to a rare but serious form of blood clots.
The country’s health authority said the benefits do not outweigh the risk of causing the possible adverse effect in those who receive the vaccine.
Will other countries follow suit?
Timestamps:
– PFE 02:30
– JNJ 04:00
Join our responsible trading community - Open your Orbex account now!